BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The applicant Hexal Biotech Forschungs GmbH submitted on 9 March 2006 an application for 
Marketing Authorisation to the European Medicines Agency (EMEA) for HX575, through the 
centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 
726/2004.  
The legal basis for this application refers to:  
Article  10(4)  of  Directive  2001/83/EC,  as  amended  –  relating  to  applications  for  similar  biological 
medicinal products. 
The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete 
quality data and appropriate non-clinical and clinical data for a similar biological medicinal product. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 22 October 2003. The Scientific Advice 
pertained to quality, non-clinical and clinical aspects of the dossier.  
Licensing status: 
New applications were filed in the following countries: South Africa. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
Eric Abadie 
Co-Rapporteur:  Harald Enzmann 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 09 March 2006.  
The procedure started on 29 March 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
16 June 2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 7 June 2006.  
During  the  meeting  on  24-27  July  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 27 July 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
22 January 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 2 March 2007. 
During  the  CHMP  meeting  on  19-22  March  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant.  
The applicant submitted the responses to the list of outstanding issues on 24 April 2007. 
During the CHMP meeting on 21 May 2007, outstanding issues were addressed by the applicant 
during an oral explanation before the CHMP. 
During the meeting on 18-21 June 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  HX575  on  21  June  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 19 June 2007. 
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
